Trevi Therapeutics/$TRVI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Ticker
$TRVI
Sector
Primary listing
Employees
34
Headquarters
Website
TRVI Metrics
BasicAdvanced
$1.5B
-
-$0.32
0.99
-
Price and volume
Market cap
$1.5B
Beta
0.99
52-week high
$14.39
52-week low
$4.85
Average daily volume
1.3M
Financial strength
Current ratio
19.659
Quick ratio
19.412
Long term debt to equity
0.243
Total debt to equity
0.411
Profitability
EBITDA (TTM)
-49.184
Effective tax rate (TTM)
0.15%
Management effectiveness
Return on assets (TTM)
-20.26%
Return on equity (TTM)
-30.23%
Valuation
Price to book
8.36
Price to tangible book (TTM)
8.36
Price to free cash flow (TTM)
-38.215
Free cash flow yield (TTM)
-2.62%
Free cash flow per share (TTM)
-0.312
Growth
Earnings per share change (TTM)
-32.46%
3-year earnings per share growth (CAGR)
-11.10%
What the Analysts think about TRVI
Analyst ratings (Buy, Hold, Sell) for Trevi Therapeutics stock.
TRVI Financial Performance
Revenues and expenses
TRVI Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Trevi Therapeutics stock?
Trevi Therapeutics (TRVI) has a market cap of $1.5B as of April 04, 2026.
What is the P/E ratio for Trevi Therapeutics stock?
The price to earnings (P/E) ratio for Trevi Therapeutics (TRVI) stock is 0 as of April 04, 2026.
Does Trevi Therapeutics stock pay dividends?
No, Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders as of April 04, 2026.
When is the next Trevi Therapeutics dividend payment date?
Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders.
What is the beta indicator for Trevi Therapeutics?
Trevi Therapeutics (TRVI) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.